Cellectis Biotherapeutics (CLLS): Price Target Chart

The linear price action on the Cellectis S.A. (CLLS) chart shows a current level of 5.01. Cellectis S.A. acts as an innovator in gene modification for the development of allogeneic CAR-T therapies. Business revenues are based on licensing fees from global pharma behemoths for access to its technologies. Despite the concentration of development within the oncology sphere, binary risks are mitigated by substantial grants and partnerships.

Cellectis Biotherapeutics - CLLS Price Target Chart (period 07/04/2022 - 11/11/2026)

Metric breakdowns and analytics for Cellectis S.A. (CLLS)

- market price and analyst price targets:

Stock Quotes cellectis.com|CLLS - Price Target Chart

- stock exchange capitalization data:

Market Value Cellectis Biotherapeutics|CLLS - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Cellectis S.A.|CLLS - Company Book Value|Market Capitalization to Book Value cellectis.com|CLLS - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

CLLS - Company Net Income|Expected Net Profit Cellectis S.A.|CLLS - P/E Multiple|Forward Price to Earnings Multiple cellectis.com|CLLS - Price/Earnings to Growth Multiple|Company Value to EBITDA Cellectis Biotherapeutics|CLLS - Operating profit before deduction of amortization|Earnings per share for the trailing year Cellectis S.A.|CLLS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months cellectis.com|CLLS - Earnings growth in current year|Expected net earnings per share growth next year Cellectis S.A.

General company analysis:CLLS (Cellectis SA)

This indicator represents a weighted average fair value assessment of the asset over a one-year horizon, aggregating expectations from leading investment houses to determine the potential for price growth. By analyzing the analysts' consensus price target, investors can gauge market optimism regarding the success of Cellectis S.A. (CLLS) in the field of TALEN genome editing and the effectiveness of its strategic alliances with pharmaceutical behemoths.

Competitors of Cellectis S.A.